Boston Scientific Corporation (ETR:BSX)
Germany · Delayed Price · Currency is EUR | Market Cap | 58.96B -54.5% |
| Revenue (ttm) | 18.55B +8.9% |
| Net Income | 3.08B +25.5% |
| EPS | 2.13 +26.6% |
| Shares Out | n/a |
| PE Ratio | 19.31 |
| Forward PE | 14.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87 |
| Open | 39.81 |
| Previous Close | 39.20 |
| Day's Range | 39.60 - 41.20 |
| 52-Week Range | 35.42 - 91.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial numbers in USD Financial StatementsNews
Boston Scientific Transcript: Stifel 2026 Healthcare Conference 2026
Interventional Therapies will unite four businesses effective Jan. 1, with broad product launches supporting durable high-single-digit growth and an aspiration for double digits. PFA and WATCHMAN face challenging dynamics through 2027, with new devices and potential coverage changes key to the longer-term outlook.
Blackstone Life Sciences announces $455M collaboration with Boston Scientific
Blackstone Life Sciences (BX) announced a $455M collaboration with Boston Scientific Corporation (BSX) to co-fund the development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Suppo...
Blackstone Life Sciences announces $455M collaboration with Boston Scientific
Blackstone Life Sciences “announced a $455 million collaboration with Boston Scientific (BSX) to co-fund the development of the VITALYST(TM) Temporary Percutaneous Transvalvular Circulatory Support Sy...
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITAL...
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens MARLBOROUGH, Mass....
Boston Scientific price target lowered to $45 from $48 at Barclays
Barclays analyst Christopher Pasquale lowered the firm’s price target on Boston Scientific (BSX) to $45 from $48 and keeps an Equal Weight rating on the shares.
Boston Scientific downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Boston Scientific (BSX) to Hold from Buy with a price target of $46, down from $56. The company guided below consensus for Q4 and made incrementally negative…
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
Boston Scientific price target lowered to $52 from $70 at RBC Capital
RBC Capital lowered the firm’s price target on Boston Scientific (BSX) to $52 from $70 and keeps an Outperform rating on the shares after its Q3 results. The downside surprise…
Boston Scientific price target lowered to $48 from $60 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Boston Scientific (BSX) to $48 from $60 and keeps a Buy rating on the shares.
Boston Scientific price target lowered to $50 from $55 at Leerink
Leerink lowered the firm’s price target on Boston Scientific (BSX) to $50 from $55 and keeps an Outperform rating on the shares. While Q3 earnings marked another downward revision of…
Boston Scientific price target lowered to $49 from $54 at Bernstein
Bernstein lowered the firm’s price target on Boston Scientific (BSX) to $49 from $54 and keeps an Outperform rating on the shares. Boston Scientific reported Q3 results yesterday, and shares…
Boston Scientific price target lowered to $57 from $67 at UBS
UBS lowered the firm’s price target on Boston Scientific (BSX) to $57 from $67 and keeps a Buy rating on the shares.
Boston Scientific price target lowered to $49 from $56 at BTIG
BTIG lowered the firm’s price target on Boston Scientific (BSX) to $49 from $56 and keeps a Buy rating on the shares. The company’s Q3 results exceeded expectations but themanagement…
Boston Scientific price target lowered to $48 from $66 at Canaccord
Canaccord lowered the firm’s price target on Boston Scientific (BSX) to $48 from $66 and keeps a Buy rating on the shares. The firm said they reported Q3 revenue of…
Boston Scientific price target lowered to $50 from $55 at Mizuho
Mizuho lowered the firm’s price target on Boston Scientific (BSX) to $50 from $55 and keeps an Outperform rating on the shares.
Boston Scientific price target lowered to $44 from $48 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Boston Scientific (BSX) to $44 from $48 and keeps a Neutral rating on the shares. The company reported better than…
Boston Scientific downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Suraj Kalia downgraded Boston Scientific (BSX) to Perform from Outperform without a price target The company reported in-line Q3 revenue but set the stage for “no growth in…
Boston Scientific price target raised to $51 from $50 at Baird
Baird raised the firm’s price target on Boston Scientific (BSX) to $51 from $50 and keeps an Outperform rating on the shares. The firm updated its model following results which…
Boston Scientific price target lowered to $50 from $55 at Leerink
Leerink analyst Mike Kratky lowered the firm’s price target on Boston Scientific (BSX) to $50 from $55 and keeps an Outperform rating on the shares.
Boston Scientific cut to Hold on limited visibility, says Jefferies
As previously reported, Jefferies analyst Matthew Taylor downgraded Boston Scientific (BSX) to Hold from Buy with a price target of $46, down from $60, after its Q3 results and below-consensus…
Boston Scientific warns of tough 2027 on China pricing, heart-device weakness
Boston Scientific warns of tough 2027 on China pricing, heart-device weakness
Boston Scientific Earnings Call Transcript: Q3 2026
Q3 growth and adjusted EPS fell short of guidance, with cyber disruption contributing materially. EP, WATCHMAN and China pricing are expected to pressure 2027, while restructuring and new launches underpin a targeted recovery in 2028.
Boston Scientific Earnings release: Q3 2026
Boston Scientific released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Boston Scientific Quarterly report: Q3 2026
Boston Scientific has published its Q3 2026 quarterly earnings report on October 28, 2026.